Literature DB >> 24346411

Comments on Wale et al. : Combined (99)mTc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules.

Ahmad Riazi1, Mohammadreza Kalantarhormozi, Iraj Nabipour, Afshin Ostovar, Hamid Javadi, Majid Assadi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24346411     DOI： 10.1007/s00259-013-2641-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Negative MIBI thyroid scans exclude differentiated and medullary thyroid cancer in 100% of patients with hypofunctioning thyroid nodules.

Authors:  Luis-Mauricio Hurtado-López; Carlos Martínez-Duncker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

2.  Technetium-99m methoxyisobutylisonitrile scintigraphy in the assessment of cold thyroid nodules: is it time to change the approach to the management of cold thyroid nodules?

Authors:  Ahmad Riazi; Mohammadreza Kalantarhormozi; Iraj Nabipour; Seyed S Eghbali; Mohammadreza Farzaneh; Hamid Javadi; Afshin Ostovar; Mohammad Seyedabadi; Majid Assadi
Journal:  Nucl Med Commun       Date:  2014-01       Impact factor: 1.690

3.  Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm.

Authors:  Maria B Albuja-Cruz; Melanie Goldfarb; Stephen S Gondek; Bassan J Allan; John I Lew
Journal:  J Surg Res       Date:  2012-07-06       Impact factor: 2.192

4.  Combined (99m)Tc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules.

Authors:  Anita Wale; Kenneth A Miles; Barnaby Young; Charles Zammit; Anthony Williams; John Quin; Sabina Dizdarevic
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-13       Impact factor: 9.236
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.